Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.
Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts. Krastinova E, et al. PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. PLoS One. 2013. PMID: 23936509 Free PMC article.
Virologically suppressed patients with asymptomatic and symptomatic HIV-associated neurocognitive disorders do not display the same pattern of immune activation.
Vassallo M, Durant J, Lebrun-Frenay C, Fabre R, Ticchioni M, Andersen S, DeSalvador F, Harvey-Langton A, Dunais B, Cohen-Codar I, Montagne N, Cua E, Fredouille-Heripret L, Laffon M, Cottalorda J, Dellamonica P, Pradier C. Vassallo M, et al. HIV Med. 2015 Aug;16(7):431-40. doi: 10.1111/hiv.12246. Epub 2015 May 18. HIV Med. 2015. PMID: 25981452 Free article.
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
Pradat P, Durant J, Brochier C, Trabaud MA, Cottalorda-Dufayard J, Izopet J, Raffi F, Lucht F, Gagnieu MC, Gatey C, Jacomet C, Vassallo M, Dellamonica P, Cotte L; No Nuc No Boost Study Group. Pradat P, et al. Among authors: vassallo m. J Antimicrob Chemother. 2016 Nov;71(11):3235-3241. doi: 10.1093/jac/dkw273. Epub 2016 Jul 17. J Antimicrob Chemother. 2016. PMID: 27432606 Clinical Trial.
A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
Vassallo M, Fabre R, Durant J, Lebrun-Frenay C, Joly H, Ticchioni M, DeSalvador F, Harvey-Langton A, Dunais B, Laffon M, Cottalorda J, Dellamonica P, Pradier C. Vassallo M, et al. J Neurovirol. 2017 Apr;23(2):216-225. doi: 10.1007/s13365-016-0490-z. Epub 2016 Nov 4. J Neurovirol. 2017. PMID: 27815816
HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Isorders (HAND).
Gougeon ML, Poirier-Beaudouin B, Durant J, Lebrun-Frenay C, Saïdi H, Seffer V, Ticchioni M, Chanalet S, Carsenti H, Harvey-Langton A, Laffon M, Cottalorda J, Pradier C, Dellamonica P, Vassallo M. Gougeon ML, et al. Among authors: vassallo m. Heliyon. 2017 Feb 13;3(2):e00245. doi: 10.1016/j.heliyon.2017.e00245. eCollection 2017 Feb. Heliyon. 2017. PMID: 28224137 Free PMC article.
298 results